Aerie Pharmaceuticals (NASDAQ:AERI) has been assigned a $73.00 target price by stock analysts at Canaccord Genuity in a note issued to investors on Monday, December 18th. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s target price indicates a potential upside of 24.57% from the company’s previous close.
A number of other analysts have also recently commented on the company. Guggenheim started coverage on Aerie Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $80.00 price target for the company. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Mizuho reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, November 3rd. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $62.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $72.00.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded down $0.20 during mid-day trading on Monday, hitting $58.60. The stock had a trading volume of 211,758 shares, compared to its average volume of 342,134. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. The company has a market cap of $2,150.00, a PE ratio of -17.49 and a beta of 1.11. Aerie Pharmaceuticals has a one year low of $38.14 and a one year high of $66.60.
Large investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its position in Aerie Pharmaceuticals by 11.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares during the last quarter. Quantbot Technologies LP boosted its position in Aerie Pharmaceuticals by 792.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after acquiring an additional 2,647 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the last quarter. Amalgamated Bank acquired a new position in Aerie Pharmaceuticals during the 2nd quarter worth approximately $204,000. Finally, Great West Life Assurance Co. Can boosted its position in Aerie Pharmaceuticals by 65.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after acquiring an additional 1,639 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $73.00 Price Target” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/aerie-pharmaceuticals-aeri-given-a-73-00-price-target-by-canaccord-genuity-analysts.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.